oxybutynin has been researched along with naltrexone in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Banks, SL; Brogden, NK; Loftin, CD; Paudel, KS; Stinchcomb, AL | 1 |
| Ghosh, P; Hammell, DC; Paudel, KS; Pinninti, RR; Stinchcomb, AL | 1 |
| Freier, A; Lorch, U; Pierscionek, T; Spencer, CS; Täubel, J | 1 |
| Gault, A; Wahl, G | 1 |
1 review(s) available for oxybutynin and naltrexone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for oxybutynin and naltrexone
| Article | Year |
|---|---|
Safety, Tolerability, and Dose Proportionality of a Novel Transdermal Fentanyl Matrix Patch and Bioequivalence With a Matrix Fentanyl Patch: Two Phase 1 Single-Center Open-Label, Randomized Crossover Studies in Healthy Japanese Volunteers.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Area Under Curve; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Compounding; Drug Delivery Systems; Drug Tolerance; Fentanyl; Healthy Volunteers; Humans; Japan; Naltrexone; Narcotic Antagonists; Reproducibility of Results; Safety; Therapeutic Equivalency; Transdermal Patch | 2021 |
6 other study(ies) available for oxybutynin and naltrexone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin.
Topics: Animals; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Diclofenac; Guinea Pigs; Naltrexone; Narcotic Antagonists; Skin; Skin Absorption; Transdermal Patch | 2011 |
Development of a codrug approach for sustained drug delivery across microneedle-treated skin.
Topics: Administration, Cutaneous; Animals; Cyclooxygenase Inhibitors; Diclofenac; Drug Delivery Systems; Guinea Pigs; Naltrexone; Narcotic Antagonists; Needles; Skin; Skin Absorption; Swine; Transdermal Patch | 2013 |
Reversal of ingested fentanyl patch toxicity with oral naltrexone in remote Australia: case report.
Topics: Administration, Oral; Adult; Analgesics, Opioid; Australia; Fentanyl; Humans; Male; Naltrexone; Opioid-Related Disorders; Out-of-Hospital Cardiac Arrest; Rural Population; Transdermal Patch; Treatment Outcome | 2021 |